Cargando…
Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection
OBJECTIVES: To evaluate the pharmacokinetics and clinical effectiveness of IV and oral fosfomycin treatment in patients with recurrent urinary tract infection (rUTI) with Escherichia coli. PATIENTS AND METHODS: Patients with rUTI treated with 3 g of oral fosfomycin every 72 h for at least 14 days we...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297308/ https://www.ncbi.nlm.nih.gov/pubmed/32712666 http://dx.doi.org/10.1093/jac/dkaa294 |
_version_ | 1784750448991797248 |
---|---|
author | Kuiper, Sander G Dijkmans, Anneke C Wilms, Erik B Kamerling, Ingrid M C Burggraaf, Jacobus Stevens, Jasper van Nieuwkoop, Cees |
author_facet | Kuiper, Sander G Dijkmans, Anneke C Wilms, Erik B Kamerling, Ingrid M C Burggraaf, Jacobus Stevens, Jasper van Nieuwkoop, Cees |
author_sort | Kuiper, Sander G |
collection | PubMed |
description | OBJECTIVES: To evaluate the pharmacokinetics and clinical effectiveness of IV and oral fosfomycin treatment in patients with recurrent urinary tract infection (rUTI) with Escherichia coli. PATIENTS AND METHODS: Patients with rUTI treated with 3 g of oral fosfomycin every 72 h for at least 14 days were included in a prospective open-label single-centre study. Serum samples were taken after oral and IV administration of fosfomycin. Urine was collected for 24 h on 3 consecutive days. Fosfomycin concentrations in serum and urine were analysed using validated LC–MS/MS. Pharmacokinetics were evaluated using a population model. EudraCT number 2018-000616-25. RESULTS: Twelve patients were included, of whom nine were also administered IV fosfomycin. Data were best described by a two-compartment model with linear elimination and a transit-absorption compartment. Median values for absolute bioavailability and serum half-life were 18% and 2.13 h, respectively. Geometric mean urine concentrations on Days 1, 2 and 3 were above an MIC of 8 mg/L after both oral and IV administration. Quality of life reported on a scale of 1–10 increased from 5.1 to 7.4 (P = 0.001). The average score of UTI symptoms decreased after fosfomycin dosing (by 3.1 points, 95% CI = −0.7 to 7.0, P = 0.10). CONCLUSIONS: Oral fosfomycin at 3 g every 72 h provides plasma and urine concentrations of fosfomycin above the MIC for E. coli. This pharmacokinetic model can be used to develop optimal dosing regimens of fosfomycin in patients with UTI. |
format | Online Article Text |
id | pubmed-9297308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92973082022-07-21 Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection Kuiper, Sander G Dijkmans, Anneke C Wilms, Erik B Kamerling, Ingrid M C Burggraaf, Jacobus Stevens, Jasper van Nieuwkoop, Cees J Antimicrob Chemother Original Research OBJECTIVES: To evaluate the pharmacokinetics and clinical effectiveness of IV and oral fosfomycin treatment in patients with recurrent urinary tract infection (rUTI) with Escherichia coli. PATIENTS AND METHODS: Patients with rUTI treated with 3 g of oral fosfomycin every 72 h for at least 14 days were included in a prospective open-label single-centre study. Serum samples were taken after oral and IV administration of fosfomycin. Urine was collected for 24 h on 3 consecutive days. Fosfomycin concentrations in serum and urine were analysed using validated LC–MS/MS. Pharmacokinetics were evaluated using a population model. EudraCT number 2018-000616-25. RESULTS: Twelve patients were included, of whom nine were also administered IV fosfomycin. Data were best described by a two-compartment model with linear elimination and a transit-absorption compartment. Median values for absolute bioavailability and serum half-life were 18% and 2.13 h, respectively. Geometric mean urine concentrations on Days 1, 2 and 3 were above an MIC of 8 mg/L after both oral and IV administration. Quality of life reported on a scale of 1–10 increased from 5.1 to 7.4 (P = 0.001). The average score of UTI symptoms decreased after fosfomycin dosing (by 3.1 points, 95% CI = −0.7 to 7.0, P = 0.10). CONCLUSIONS: Oral fosfomycin at 3 g every 72 h provides plasma and urine concentrations of fosfomycin above the MIC for E. coli. This pharmacokinetic model can be used to develop optimal dosing regimens of fosfomycin in patients with UTI. Oxford University Press 2020-07-26 /pmc/articles/PMC9297308/ /pubmed/32712666 http://dx.doi.org/10.1093/jac/dkaa294 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Research Kuiper, Sander G Dijkmans, Anneke C Wilms, Erik B Kamerling, Ingrid M C Burggraaf, Jacobus Stevens, Jasper van Nieuwkoop, Cees Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection |
title | Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection |
title_full | Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection |
title_fullStr | Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection |
title_full_unstemmed | Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection |
title_short | Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection |
title_sort | pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent escherichia coli urinary tract infection |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297308/ https://www.ncbi.nlm.nih.gov/pubmed/32712666 http://dx.doi.org/10.1093/jac/dkaa294 |
work_keys_str_mv | AT kuipersanderg pharmacokineticsoffosfomycininpatientswithprophylactictreatmentforrecurrentescherichiacoliurinarytractinfection AT dijkmansannekec pharmacokineticsoffosfomycininpatientswithprophylactictreatmentforrecurrentescherichiacoliurinarytractinfection AT wilmserikb pharmacokineticsoffosfomycininpatientswithprophylactictreatmentforrecurrentescherichiacoliurinarytractinfection AT kamerlingingridmc pharmacokineticsoffosfomycininpatientswithprophylactictreatmentforrecurrentescherichiacoliurinarytractinfection AT burggraafjacobus pharmacokineticsoffosfomycininpatientswithprophylactictreatmentforrecurrentescherichiacoliurinarytractinfection AT stevensjasper pharmacokineticsoffosfomycininpatientswithprophylactictreatmentforrecurrentescherichiacoliurinarytractinfection AT vannieuwkoopcees pharmacokineticsoffosfomycininpatientswithprophylactictreatmentforrecurrentescherichiacoliurinarytractinfection |